VRI launches probiotics into pharmacies
Wednesday, 12 May, 2004
VRI BioMedical announced today that its probiotics range for the treatment of irritable bowel syndrome, diarrhoea and general intestinal health, is due to hit pharmacy shelves.
The probiotics – marketed as ‘proTract’ - are a strain of Lactobacillus Fermentum, shown to have a mucosal immune boosting action.
Unlike other probiotics, which must be refrigerated, the microorganisms are hardy enough to be freeze-dried and encapsulated.
“The proTract range is a result of research and clinical trial data which has shown particular probiotics strains to be effective in the treatment of a range of gut related conditions,” said VRI managing director Dr Peter French.
“Until now there has been no effective treatment of IBS, with a focus on symptoms such as diarrhoea or bloating, but no attempt to address the underlying causes.”
VRI BioMedical last week appointed Prof Ron Penny, AO, and Professor Terry Bolin to the company’s Scientific and Medical Advisory Board.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
